WeTrials
Recruiting

A Phase Ib Study of AZD9291 (Osimertinib) and BC2059 (Tegavivint) as First-Line Therapy in Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

What is this study?

This study is testing a combination of two cancer medications, osimertinib and tegavivint, as a first-line treatment for a specific type of advanced lung cancer. Researchers want to find the safest and most effective doses to help stop tumor growth.

Who can participate?

You may be able to join if you are 18 or older, have non-small cell lung cancer that has spread, and your tumor has specific EGFR genetic mutations. You also must not have received prior treatment with certain targeted cancer pills.

What will happen?

Participants will take the study medications and undergo regular health checks, including imaging scans like X-rays, heart function tests, and occasional tissue or fluid samples. The medical team will closely monitor you for any side effects.

Where and when?

This study is currently recruiting participants and takes place in Columbus, Ohio, in the United States.

Key Points
  • 1Tests a combination of two targeted cancer medications.
  • 2Designed for adults with specific EGFR-mutant lung cancer.
  • 3Involves regular check-ups, scans, and safety monitoring.

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Metastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.